Hossein Kamali
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hossein Kamali has a total of 113 co-authors. Here are the top co-authors by number of shared publications:
- Ali Nokhodchi
School of Life Sciences, University of Sussex, Brighton BN1 9QG, UK
8 shared publications - Elham Khodaverdi
Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
7 shared publications Elham Khodaverdi
Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Science, Mashhad, Iran
6 shared publicationsFarzin Hadizadeh
Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
6 shared publications- Farzin Hadizadeh
Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
5 shared publications Malihe Karimi
Department of Pharmaceutics, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
5 shared publications
Latest Publications
- 13 August 2026
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 52 (10) , 1929-1947
Linoleic acid–based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations
Colon-targeted drug delivery systems are designed to facilitate the passage of therapeutic agents through the upper gastrointestinal tract (GIT), enabling site-specific release and absorption withi...
- 13 August 2026
- Published by Taylor & Francis in Drug Development and Industrial Pharmacy
- Vol. 52 (10) , 1929-1947
Linoleic acid–based pH-sensitive 5-ASA nanocubosome pellets for colon targeting in ulcerative colitis: in vitro and in vivo comparison with non-pH-sensitive and conventional formulations
Colon-targeted drug delivery systems are designed to facilitate the passage of therapeutic agents through the upper gastrointestinal tract (GIT), enabling site-specific release and absorption withi...
- 24 June 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (8) , 1-19
Injectable in-situ Forming Lipid Liquid Crystal for Long-acting Fluocinolone Release in Posterior Ocular Therapy: In-vitro and In-vivo Evaluations
Objective Intravitreal injection is a preferred route for targeted drug delivery to the posterior eye. However, commercial non-biodegradable polymeric implants for fluocinolone acetonide (FA) often necessitate surgical removal after long-term release, reducing patient compliance and increase surgical risks. Biodegradable polymeric implants also typically exhibit an initial burst release. This study explores the development of an innovative biodegradable in-situ forming lipid liquid crystal (ISF-LLC) formulation for sustained FA delivery over two months via a single intravitreal injection without burst release. Methods The optimized formulation, developed using Design of Experiment software, comprised phosphatidylcholine and sorbitan monooleate (PC: SMO 30/70 w/w%) with N-methyl-2-pyrrolidone (NMP 30w/w%). Results The ISF-LLC formulation exhibited pseudoplastic behavior, excellent syringeability, stability, and a hexagonal crystalline structure. In-vivo pharmacokinetic analysis in rabbit vitreous humor revealed a slow, controlled release rate of 0.49 ± 0.01 μg/day over 60 days (within the clinical range 0.2–0.6 μg/day), with no burst release during the first 7 days (0.22 ± 0.01 μg/day). The vitreal half-life was 22.80 ± 0.51 days, and FA was undetectable systemically. Quantitative histopathology showed no significant differences in retinal thickness (203–209 μm vs. 203 ± 2 μm, p > 0.05) or inflammatory cell count (1–3 vs. 1.3 ± 0.6 cells/field, p > 0.05) between treated and control groups. No retinal damage or systemic toxicity was observed. Conclusions The injectable biodegradable ISF-LLC formulation is a promising controlled-release, long-acting platform for intravitreal drug delivery, eliminating initial burst release and need for surgical removal, thereby improving patient outcomes in ocular therapy. Graphical Abstract
- 24 June 2026
- Published by Springer Nature in Pharmaceutical Research
- Vol. 43 (8) , 1-19
Injectable in-situ Forming Lipid Liquid Crystal for Long-acting Fluocinolone Release in Posterior Ocular Therapy: In-vitro and In-vivo Evaluations
Objective Intravitreal injection is a preferred route for targeted drug delivery to the posterior eye. However, commercial non-biodegradable polymeric implants for fluocinolone acetonide (FA) often necessitate surgical removal after long-term release, reducing patient compliance and increase surgical risks. Biodegradable polymeric implants also typically exhibit an initial burst release. This study explores the development of an innovative biodegradable in-situ forming lipid liquid crystal (ISF-LLC) formulation for sustained FA delivery over two months via a single intravitreal injection without burst release. Methods The optimized formulation, developed using Design of Experiment software, comprised phosphatidylcholine and sorbitan monooleate (PC: SMO 30/70 w/w%) with N-methyl-2-pyrrolidone (NMP 30w/w%). Results The ISF-LLC formulation exhibited pseudoplastic behavior, excellent syringeability, stability, and a hexagonal crystalline structure. In-vivo pharmacokinetic analysis in rabbit vitreous humor revealed a slow, controlled release rate of 0.49 ± 0.01 μg/day over 60 days (within the clinical range 0.2–0.6 μg/day), with no burst release during the first 7 days (0.22 ± 0.01 μg/day). The vitreal half-life was 22.80 ± 0.51 days, and FA was undetectable systemically. Quantitative histopathology showed no significant differences in retinal thickness (203–209 μm vs. 203 ± 2 μm, p > 0.05) or inflammatory cell count (1–3 vs. 1.3 ± 0.6 cells/field, p > 0.05) between treated and control groups. No retinal damage or systemic toxicity was observed. Conclusions The injectable biodegradable ISF-LLC formulation is a promising controlled-release, long-acting platform for intravitreal drug delivery, eliminating initial burst release and need for surgical removal, thereby improving patient outcomes in ocular therapy. Graphical Abstract
- 4 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats
Intranasal drug delivery provides rapid absorption and high bioavailability while reducing systemic exposure, making it a hopeful route for nose-to-brain (N2B) transport. However, no effective N2B system has yet been systematically studied for cetrorelix, which is a GnRH antagonist used in reproductive medicine. In this study, a cetrorelix-loaded chitosan-Pluronic F-127 (Chi-Plx) nanoparticle system with a complementary Plx in-situ gel to extend nasal residence time was developed. The formulations were characterized for physicochemical properties, release behavior, cytotoxicity, and pharmacokinetics in rats. Chi-Plx nanoparticles exhibited a mean diameter of 18.7 ± 2.1 nm, PDI of 0.35 ± 0.03, and near-neutral zeta potential. They demonstrated a biphasic release profile with an initial burst (52%) followed by sustained release, achieving 70-80% cumulative release at 1440 min, while the in-situ gel released 65-70% over the same period. Cytotoxicity assays confirmed acceptable biocompatibility, with lower toxicity than the gel formulation. Pharmacokinetic analysis revealed that Chi-Plx nanoparticles achieved markedly higher brain Cmax (223.6 ± 3.6 ng/ml) and drug targeting efficiency (81.8 ± 0.7) compared to the in-situ gel (Cmax 81.6 ng/ml; Drug targeting efficiency (DTE) 34.7) and subcutaneous injection (Cmax 218.2 ng/ml; Drug targeting efficiency (DTE) 1.0). Serum exposure was substantially reduced after intranasal administration, minimizing systemic distribution. This study demonstrates, for the first time, that cetrorelix-loaded Chi-Plx nanoparticles can efficiently deliver peptide drugs to the brain via the intranasal route, offering a promising, needle-free strategy to enhance patient compliance and reduce adverse effects in GnRH-related therapies.
- 4 June 2026
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 27 (5)
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats
Intranasal drug delivery provides rapid absorption and high bioavailability while reducing systemic exposure, making it a hopeful route for nose-to-brain (N2B) transport. However, no effective N2B system has yet been systematically studied for cetrorelix, which is a GnRH antagonist used in reproductive medicine. In this study, a cetrorelix-loaded chitosan-Pluronic F-127 (Chi-Plx) nanoparticle system with a complementary Plx in-situ gel to extend nasal residence time was developed. The formulations were characterized for physicochemical properties, release behavior, cytotoxicity, and pharmacokinetics in rats. Chi-Plx nanoparticles exhibited a mean diameter of 18.7 ± 2.1 nm, PDI of 0.35 ± 0.03, and near-neutral zeta potential. They demonstrated a biphasic release profile with an initial burst (52%) followed by sustained release, achieving 70-80% cumulative release at 1440 min, while the in-situ gel released 65-70% over the same period. Cytotoxicity assays confirmed acceptable biocompatibility, with lower toxicity than the gel formulation. Pharmacokinetic analysis revealed that Chi-Plx nanoparticles achieved markedly higher brain Cmax (223.6 ± 3.6 ng/ml) and drug targeting efficiency (81.8 ± 0.7) compared to the in-situ gel (Cmax 81.6 ng/ml; Drug targeting efficiency (DTE) 34.7) and subcutaneous injection (Cmax 218.2 ng/ml; Drug targeting efficiency (DTE) 1.0). Serum exposure was substantially reduced after intranasal administration, minimizing systemic distribution. This study demonstrates, for the first time, that cetrorelix-loaded Chi-Plx nanoparticles can efficiently deliver peptide drugs to the brain via the intranasal route, offering a promising, needle-free strategy to enhance patient compliance and reduce adverse effects in GnRH-related therapies.
- Open Access
- 10 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 286
Eugenol- and Iodoform-Loaded Lipid Liquid Crystal Dressing for Alveolar Osteitis: Formulation, In Vitro Evaluation, and a Double-Blind Randomized Clinical Trial
Purpose: This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO). Methods: Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl ® for pain, analgesic use, and dressing applications over seven days. Results: The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl ® at all assessed time points, with no significant differences (0 h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; p > 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, P = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, P = 0.345) showed similar efficiency. Conclusion: The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl ® for the management of AO.
- 10 March 2026
- Published by Springer Nature in Journal of Pharmaceutical Innovation
- Vol. 21 (3) , 286
Open AccessEugenol- and Iodoform-Loaded Lipid Liquid Crystal Dressing for Alveolar Osteitis: Formulation, In Vitro Evaluation, and a Double-Blind Randomized Clinical Trial
Purpose: This study aimed to formulate and clinically evaluate a novel lipid liquid crystal (LLC) dressing containing eugenol and iodoform, designed for sustained release, antimicrobial activity, and pain relief in alveolar osteitis (AO). Methods: Formulations with varying ratios of phosphatidylcholine (PC), sorbitan monooleate (SMO), glyceryl monooleate (GMO), and N-methyl-2-pyrrolidone (NMP) were prepared. The formulation which showed a good physicochemical stability and suitable viscosity was selected for further studies (F17, the optimized formulation). The optimized formulation was characterized for physicochemical properties and in vitro release. In a double-blind, randomized trial with 60 AO patients, the LLC-dressing was compared to Alvogyl ® for pain, analgesic use, and dressing applications over seven days. Results: The optimized formulation (F17) contained 35.25% PC, 35.25% SMO, 13.7% eugenol, and 15.8% iodoform, demonstrating an improved sustained drug release profile, appropriate viscosity, effective antibacterial activity, 100% encapsulation efficiency, and drug loading of 13.7% (eugenol) and 15.8% (iodoform). Visual Analog Scale (VAS) pain scores were comparable between LLC-dressing and Alvogyl ® at all assessed time points, with no significant differences (0 h: 8.14 ± 1.40 vs. 7.96 ± 1.02; 7 days: 0.70 ± 0.66 vs. 0.78 ± 0.60; p > 0.05). Analgesic use (5.51 ± 3.06 vs. 6.13 ± 2.87, P = 0.401) and dressing applications (2.27 ± 1.12 vs. 2.57 ± 1.20, P = 0.345) showed similar efficiency. Conclusion: The optimized LLC-dressing (F17) exhibits favorable physicochemical and in vitro characteristics and may be considered a potential alternative to Alvogyl ® for the management of AO.
- Open Access
- 1 July 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (6) , 1-19
Intranasal Delivery of Cetrorelix Via Lipid Liquid Crystal Nanoparticles: Characterization and Pharmacokinetic Studies in Rats
Nasal sprays are extensively researched due to their rapid absorption, high bioavailability, and low side effects. Lipid liquid crystal nanoparticles (LLCNs) are being considered as potential carriers for intranasal delivery. LLCs loaded with cetrorelix (GnRH antagonist) were utilized for intranasal drug delivery to enhance brain targeting while minimizing systemic exposure. A single-phase formulation incorporating HPMC as a mucoadhesive was developed to extend nasal residence time. Following intranasal administration of cetrorelix in rats, its distribution in various brain regions and serum was assessed using LC–MS-MS. In the LLC formulation, the particle diameter, PDI, and Zeta potential were measured as 204.92 ± 0.89 nm, 0.188 ± 0.019, and -21.63 ± 1.72 mV, respectively. A monomodal distribution and low polydispersity index were observed, along with a negative zeta potential. Cetrorelix was released from the LLC in a biphasic profile, with an initial burst release of 30%, followed by a gradual and sustained release phase. The LLCs containing cetrorelix exhibited lower cytotoxicity compared to the LLC base. The nasal administration of cetrorelix via LLCs presents a promising advancement for nose-to-brain drug transport. The pharmacokinetic data demonstrated that the AUC0-360min for brain tissue analysis, following nasal administration of the single-phase formulation, was 3.104 ng/ml.min. The value was 7.104 ng/ml.min for LLC nasal administration and 6.104 ng/ml.min for subcutaneous injection. The maximum concentration (Cmax) values for brain tissue analysis indicated a significant increase with LLC nasal administration (238 ± 6. 2 ng/ml) in comparison to the single-phase formulation (202.5 ± 6.3 ng/ml) and subcutaneous injection (218.2 ± 3. 1 ng/ml). In serum analysis, the Cmax values were significantly elevated, with subcutaneous injection achieving (4983.3 ± 2.5 ng/ml), followed by LLC nasal administration at (93.1 ± 6.2 ng/ml), and the single-phase formulation at (43.7 ± 2.2 ng/ml). This innovative method aims to target the brain directly, eliminating the need for needles, and reducing adverse effects, hence offering new hope for brain-targeted drug delivery. This study introduces, for the first time, a cetrorelix-loaded lipid liquid crystal (LLC) nanoparticle formulation for intranasal nose-to-brain delivery. The LLC system achieved enhanced brain targeting efficiency while reducing systemic exposure compared to conventional subcutaneous injections and simple nasal formulations, representing a promising advancement in GnRH drug delivery strategies. Graphical Abstract
- 1 July 2025
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 26 (6) , 1-19
Open AccessIntranasal Delivery of Cetrorelix Via Lipid Liquid Crystal Nanoparticles: Characterization and Pharmacokinetic Studies in Rats
Nasal sprays are extensively researched due to their rapid absorption, high bioavailability, and low side effects. Lipid liquid crystal nanoparticles (LLCNs) are being considered as potential carriers for intranasal delivery. LLCs loaded with cetrorelix (GnRH antagonist) were utilized for intranasal drug delivery to enhance brain targeting while minimizing systemic exposure. A single-phase formulation incorporating HPMC as a mucoadhesive was developed to extend nasal residence time. Following intranasal administration of cetrorelix in rats, its distribution in various brain regions and serum was assessed using LC–MS-MS. In the LLC formulation, the particle diameter, PDI, and Zeta potential were measured as 204.92 ± 0.89 nm, 0.188 ± 0.019, and -21.63 ± 1.72 mV, respectively. A monomodal distribution and low polydispersity index were observed, along with a negative zeta potential. Cetrorelix was released from the LLC in a biphasic profile, with an initial burst release of 30%, followed by a gradual and sustained release phase. The LLCs containing cetrorelix exhibited lower cytotoxicity compared to the LLC base. The nasal administration of cetrorelix via LLCs presents a promising advancement for nose-to-brain drug transport. The pharmacokinetic data demonstrated that the AUC0-360min for brain tissue analysis, following nasal administration of the single-phase formulation, was 3.104 ng/ml.min. The value was 7.104 ng/ml.min for LLC nasal administration and 6.104 ng/ml.min for subcutaneous injection. The maximum concentration (Cmax) values for brain tissue analysis indicated a significant increase with LLC nasal administration (238 ± 6. 2 ng/ml) in comparison to the single-phase formulation (202.5 ± 6.3 ng/ml) and subcutaneous injection (218.2 ± 3. 1 ng/ml). In serum analysis, the Cmax values were significantly elevated, with subcutaneous injection achieving (4983.3 ± 2.5 ng/ml), followed by LLC nasal administration at (93.1 ± 6.2 ng/ml), and the single-phase formulation at (43.7 ± 2.2 ng/ml). This innovative method aims to target the brain directly, eliminating the need for needles, and reducing adverse effects, hence offering new hope for brain-targeted drug delivery. This study introduces, for the first time, a cetrorelix-loaded lipid liquid crystal (LLC) nanoparticle formulation for intranasal nose-to-brain delivery. The LLC system achieved enhanced brain targeting efficiency while reducing systemic exposure compared to conventional subcutaneous injections and simple nasal formulations, representing a promising advancement in GnRH drug delivery strategies. Graphical Abstract
- Open Access
- 27 May 2025
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 30 (5) , 572-589
Lycopene-carrier solid dispersion loaded lipid liquid crystal nanoparticle: in vitro evaluation and in vivo wound healing effects
This study was conducted to develop a lycopene-carrier solid dispersion-loaded lipid liquid crystal nanoparticle (LLC) formulation aimed at enhancing aqueous solubility, bioavailability, and wound healing efficacy. Lycopene was extracted from tomato paste using the Soxhlet method and was formulated into solid dispersions with polyvinylpyrrolidone (PVP) and Poloxamer (Plx) to enhance the solubility of lycopene. The physicochemical properties of the solid dispersion products were characterized. Cytotoxicity on human fibroblast cells, cell migration, and wound healing treatment in the mice were also assessed. PVP demonstrated greater efficacy in enhancing the aqueous solubility of lycopene than Plx. The results indicated that the morphology of the LLC was cubosome, achieving a high encapsulation efficiency of 71.57 ± 2.1%. The LLC formulations demonstrated significantly enhanced release rates of 68.18 ± 1.78% and improved skin permeation compared to the lycopene solid dispersion solution. The results of the cell culture demonstrated the safety of the formulation, and the in vitro scratch test showed the migration of fibroblast cells in the presence of the lycopene-PVP solid dispersion loaded LLC compared to lycopene alone. Based on the obtained results, it can be concluded that the proposed formulation (lycopene-PVP solid dispersion loaded LLC) could be a suitable option for wound healing.
- 27 May 2025
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 30 (5) , 572-589
Open AccessLycopene-carrier solid dispersion loaded lipid liquid crystal nanoparticle: in vitro evaluation and in vivo wound healing effects
This study was conducted to develop a lycopene-carrier solid dispersion-loaded lipid liquid crystal nanoparticle (LLC) formulation aimed at enhancing aqueous solubility, bioavailability, and wound healing efficacy. Lycopene was extracted from tomato paste using the Soxhlet method and was formulated into solid dispersions with polyvinylpyrrolidone (PVP) and Poloxamer (Plx) to enhance the solubility of lycopene. The physicochemical properties of the solid dispersion products were characterized. Cytotoxicity on human fibroblast cells, cell migration, and wound healing treatment in the mice were also assessed. PVP demonstrated greater efficacy in enhancing the aqueous solubility of lycopene than Plx. The results indicated that the morphology of the LLC was cubosome, achieving a high encapsulation efficiency of 71.57 ± 2.1%. The LLC formulations demonstrated significantly enhanced release rates of 68.18 ± 1.78% and improved skin permeation compared to the lycopene solid dispersion solution. The results of the cell culture demonstrated the safety of the formulation, and the in vitro scratch test showed the migration of fibroblast cells in the presence of the lycopene-PVP solid dispersion loaded LLC compared to lycopene alone. Based on the obtained results, it can be concluded that the proposed formulation (lycopene-PVP solid dispersion loaded LLC) could be a suitable option for wound healing.
- Open Access
- 5 December 2024
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 70-81
Preparation and in-vitro characterization of triamcinolone acetonide-loaded lipid liquid crystal nanocarriers for ocular delivery
Purpose: This study aimed to develop sustained-release Triamcinolone acetonide (TA) formulations using lipid liquid crystals (LLC) for ocular drug delivery and to characterize the designed formulations. Method: Eighteen dispersed LLC formulations were prepared through a top-down approach, incorporating varying concentrations of TA and different proportions of glyceryl monooleate, deionized water, and Pluronic F127. An additional formulation comprising TA: HPβCD complex was also developed to investigate the influence of hydroxypropyl beta-cyclodextrin (HPβCD) on the properties of the formulations. The formulations were evaluated for their rheological properties in room temperature using a rheometer, syringeability by passing them through a 27G needle, size measurements via dynamic light scattering, and morphology through polarized light microscopy (PLM). Furthermore, the prepared formulations were injected into a dialysis tube and placed in a phosphate buffer at pH 7.4 and 37°C for in vitro release evaluation. Samples were taken at predetermined intervals and stored in a refrigerator until HPLC analysis. The percentage of Encapsulation efficacy and drug loading were evaluated using an indirect method. A reversed-phase HPLC method was employed to quantify the drug concentrations in the samples. Results: All selected formulations demonstrated acceptable parameters, including particle size (less than 200 nm), polydispersity index ranging from 0.202 to 0.355, and zeta potential values between -14.3 and -32.8 mV. Additionally, the formulations showed good syringeability and achieved 100% drug release within 48 hours (except for the formulation containing HPβCD). PLM analysis revealed the presence of hexosomes and cubosomes, indicating that an increase in hexosomes contributed to a more uniform drug release from the formulations. Conclusion: Overall, the study findings suggest that liquid crystalline carriers can be a promising formulation for sustained ocular drug delivery of TA.
- 5 December 2024
- Published by Maad Rayan Publishing Company in Advanced Pharmaceutical Bulletin
- Vol. 15 (1) , 70-81
Open AccessPreparation and in-vitro characterization of triamcinolone acetonide-loaded lipid liquid crystal nanocarriers for ocular delivery
Purpose: This study aimed to develop sustained-release Triamcinolone acetonide (TA) formulations using lipid liquid crystals (LLC) for ocular drug delivery and to characterize the designed formulations. Method: Eighteen dispersed LLC formulations were prepared through a top-down approach, incorporating varying concentrations of TA and different proportions of glyceryl monooleate, deionized water, and Pluronic F127. An additional formulation comprising TA: HPβCD complex was also developed to investigate the influence of hydroxypropyl beta-cyclodextrin (HPβCD) on the properties of the formulations. The formulations were evaluated for their rheological properties in room temperature using a rheometer, syringeability by passing them through a 27G needle, size measurements via dynamic light scattering, and morphology through polarized light microscopy (PLM). Furthermore, the prepared formulations were injected into a dialysis tube and placed in a phosphate buffer at pH 7.4 and 37°C for in vitro release evaluation. Samples were taken at predetermined intervals and stored in a refrigerator until HPLC analysis. The percentage of Encapsulation efficacy and drug loading were evaluated using an indirect method. A reversed-phase HPLC method was employed to quantify the drug concentrations in the samples. Results: All selected formulations demonstrated acceptable parameters, including particle size (less than 200 nm), polydispersity index ranging from 0.202 to 0.355, and zeta potential values between -14.3 and -32.8 mV. Additionally, the formulations showed good syringeability and achieved 100% drug release within 48 hours (except for the formulation containing HPβCD). PLM analysis revealed the presence of hexosomes and cubosomes, indicating that an increase in hexosomes contributed to a more uniform drug release from the formulations. Conclusion: Overall, the study findings suggest that liquid crystalline carriers can be a promising formulation for sustained ocular drug delivery of TA.